ID   GCR_RAT                 Reviewed;         795 AA.
AC   P06536; O08624; Q8R463; Q8R5J0;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   02-OCT-2024, entry version 246.
DE   RecName: Full=Glucocorticoid receptor;
DE            Short=GR;
DE   AltName: Full=Nuclear receptor subfamily 3 group C member 1;
GN   Name=Nr3c1; Synonyms=Grl;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hepatoma;
RX   PubMed=3755378; DOI=10.1016/0092-8674(86)90659-8;
RA   Miesfeld R., Rusconi S., Godowski P.J., Maler B.A., Okret S.,
RA   Wikstroem A.-C., Gustafsson J.-A., Yamamoto K.R.;
RT   "Genetic complementation of a glucocorticoid receptor deficiency by
RT   expression of cloned receptor cDNA.";
RL   Cell 46:389-399(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Heeley R.P., Gill E., van Zutphen B.;
RT   "CAG repeat variation in the gene for rat glucocorticoid receptor: a study
RT   of allele frequencies in inbred and wild rat populations and of the
RT   steroid-binding properties of their polypeptides in vitro.";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLY-226 AND ASP-260.
RC   STRAIN=Brown Norway/Crl, and SHR/OlaIpcv;
RA   Pravenec M., Zidek V., Kostka V., Mlejnek P., Musilova A., Kren V.,
RA   Jansa P., Forejt J., Lezin E.S., Kurtz T.W.;
RT   "Genetic isolation of a QTL on chromosome 18 associated with salt
RT   sensitivity in spontaneously hypertensive rats.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-515.
RC   STRAIN=Sprague-Dawley; TISSUE=Prostate;
RX   PubMed=3684608; DOI=10.1093/nar/15.22.9603;
RA   Chang C., Kokontis J., Chang C.T., Liao S.;
RT   "Cloning and sequence analysis of the rat ventral prostate glucocorticoid
RT   receptor cDNA.";
RL   Nucleic Acids Res. 15:9603-9603(1987).
RN   [5]
RP   MUTAGENESIS OF ZINC-FINGER.
RX   PubMed=3191912; DOI=10.1002/j.1460-2075.1988.tb03097.x;
RA   Severne Y., Wieland S., Schaffner W., Rusconi S.;
RT   "Metal binding 'finger' structures in the glucocorticoid receptor defined
RT   by site-directed mutagenesis.";
RL   EMBO J. 7:2503-2508(1988).
RN   [6]
RP   GLUCOCORTICOID-MEDIATED DOWN-REGULATION.
RX   PubMed=3216865; DOI=10.1210/mend-2-12-1256;
RA   Dong Y., Poellinger L., Gustafsson J.-A., Okret S.;
RT   "Regulation of glucocorticoid receptor expression: evidence for
RT   transcriptional and posttranslational mechanisms.";
RL   Mol. Endocrinol. 2:1256-1264(1988).
RN   [7]
RP   MUTAGENESIS OF CYS-656.
RX   PubMed=1939229; DOI=10.1016/s0021-9258(18)54533-6;
RA   Chakraborti P.K., Garabedian M.J., Yamamoto K.R., Simons S.S. Jr.;
RT   "Creation of 'super' glucocorticoid receptors by point mutations in the
RT   steroid binding domain.";
RL   J. Biol. Chem. 266:22075-22078(1991).
RN   [8]
RP   MUTAGENESIS OF ZINC-FINGER.
RX   PubMed=8450530; DOI=10.1006/jmbi.1993.1130;
RA   Zandi E., Galli I., Doebbeling U., Rusconi S.;
RT   "Zinc finger mutations that alter domain interactions in the glucocorticoid
RT   receptor.";
RL   J. Mol. Biol. 230:124-136(1993).
RN   [9]
RP   REVIEW ON MUTAGENESIS.
RX   PubMed=8191545; DOI=10.1016/0039-128x(94)90093-0;
RA   Lanz R.B., Hug M., Gola M., Tallone T., Wieland S., Rusconi S.;
RT   "Active, interactive, and inactive steroid receptor mutants.";
RL   Steroids 59:148-152(1994).
RN   [10]
RP   HOMODIMERIZATION, HETERODIMERIZATION WITH NR3C2, AND MUTAGENESIS OF
RP   ASP-481.
RX   PubMed=8618925; DOI=10.1073/pnas.92.26.12480;
RA   Liu W., Wang J., Sauter N.K., Pearce D.;
RT   "Steroid receptor heterodimerization demonstrated in vitro and in vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:12480-12484(1995).
RN   [11]
RP   INTERACTION WITH NCOA2.
RX   PubMed=9111344; DOI=10.1128/mcb.17.5.2735;
RA   Hong H., Kohli K., Garabedian M.J., Stallcup M.R.;
RT   "GRIP1, a transcriptional coactivator for the AF-2 transactivation domain
RT   of steroid, thyroid, retinoid, and vitamin D receptors.";
RL   Mol. Cell. Biol. 17:2735-2744(1997).
RN   [12]
RP   PHOSPHORYLATION AT THR-171; SER-224; SER-232 AND SER-246.
RX   PubMed=9603939; DOI=10.1074/jbc.273.23.14315;
RA   Rogatsky I., Waase C.L.M., Garabedian M.J.;
RT   "Phosphorylation and inhibition of rat glucocorticoid receptor
RT   transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-
RT   specific differences between human and rat glucocorticoid receptor
RT   signaling as revealed through GSK-3 phosphorylation.";
RL   J. Biol. Chem. 273:14315-14321(1998).
RN   [13]
RP   INTERACTION WITH NRIP1.
RX   PubMed=10364267; DOI=10.1074/jbc.274.25.18121;
RA   Subramaniam N., Treuter E., Okret S.;
RT   "Receptor interacting protein RIP140 inhibits both positive and negative
RT   gene regulation by glucocorticoids.";
RL   J. Biol. Chem. 274:18121-18127(1999).
RN   [14]
RP   INTERACTION WITH POU2F1 AND POU2F2, AND MUTAGENESIS OF CYS-500 AND LEU-501.
RX   PubMed=10480874; DOI=10.1074/jbc.274.38.26713;
RA   Prefontaine G.G., Walther R., Giffin W., Lemieux M.E., Pope L.,
RA   Hache R.J.G.;
RT   "Selective binding of steroid hormone receptors to octamer transcription
RT   factors determines transcriptional synergism at the mouse mammary tumor
RT   virus promoter.";
RL   J. Biol. Chem. 274:26713-26719(1999).
RN   [15]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10866662; DOI=10.1128/mcb.20.14.5048-5063.2000;
RA   Mahajan M.A., Samuels H.H.;
RT   "A new family of nuclear receptor coregulators that integrates nuclear
RT   receptor signaling through CBP.";
RL   Mol. Cell. Biol. 20:5048-5063(2000).
RN   [16]
RP   HOMODIMERIZATION, HETERODIMERIZATION WITH NR3C2, AND MUTAGENESIS OF
RP   LEU-501.
RX   PubMed=11278286; DOI=10.1074/jbc.m005363200;
RA   Ou X.-M., Storring J.M., Kushwaha N., Albert P.R.;
RT   "Heterodimerization of mineralocorticoid and glucocorticoid receptors at a
RT   novel negative response element of the 5-HT1A receptor gene.";
RL   J. Biol. Chem. 276:14299-14307(2001).
RN   [17]
RP   ALTERNATIVE INITIATION, AND MUTAGENESIS OF MET-1 AND MET-28.
RX   PubMed=11435610; DOI=10.1210/mend.15.7.0667;
RA   Yudt M.R., Cidlowski J.A.;
RT   "Molecular identification and characterization of A and B forms of the
RT   glucocorticoid receptor.";
RL   Mol. Endocrinol. 15:1093-1103(2001).
RN   [18]
RP   INTERACTION WITH NCOA1, AND MUTAGENESIS OF GLU-773.
RX   PubMed=12118039; DOI=10.1074/jbc.m204013200;
RA   Kucera T., Waltner-Law M., Scott D.K., Prasad R., Granner D.K.;
RT   "A point mutation of the AF2 transactivation domain of the glucocorticoid
RT   receptor disrupts its interaction with steroid receptor coactivator 1.";
RL   J. Biol. Chem. 277:26098-26102(2002).
RN   [19]
RP   FUNCTION, INTERACTION WITH NCOA1; NCOA3; SMARCA4; SMARCC1; SMARCD1 AND
RP   SMARCE1, AND MUTAGENESIS OF ARG-488.
RX   PubMed=12917342; DOI=10.1128/mcb.23.17.6210-6220.2003;
RA   Hsiao P.W., Fryer C.J., Trotter K.W., Wang W., Archer T.K.;
RT   "BAF60a mediates critical interactions between nuclear receptors and the
RT   BRG1 chromatin-remodeling complex for transactivation.";
RL   Mol. Cell. Biol. 23:6210-6220(2003).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16641100; DOI=10.1073/pnas.0600895103;
RA   Hoffert J.D., Pisitkun T., Wang G., Shen R.-F., Knepper M.A.;
RT   "Quantitative phosphoproteomics of vasopressin-sensitive renal cells:
RT   regulation of aquaporin-2 phosphorylation at two sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7159-7164(2006).
RN   [21]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=21730050; DOI=10.1074/jbc.m111.256610;
RA   Gallo L.I., Lagadari M., Piwien-Pilipuk G., Galigniana M.D.;
RT   "The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a
RT   mitochondrial protein that translocates to the nucleus to protect cells
RT   against oxidative stress.";
RL   J. Biol. Chem. 286:30152-30160(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-224; SER-232 AND SER-287,
RP   VARIANT [LARGE SCALE ANALYSIS] GLY-226, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [23]
RP   SUMOYLATION AT LYS-297; LYS-313 AND LYS-721, INTERACTION WITH UBE2I/UBC9
RP   AND RWDD3, AND MUTAGENESIS OF LYS-297; LYS-313 AND LYS-721.
RX   PubMed=23508108; DOI=10.1128/mcb.01470-12;
RA   Druker J., Liberman A.C., Antunica-Noguerol M., Gerez J., Paez-Pereda M.,
RA   Rein T., Iniguez-Lluhi J.A., Holsboer F., Arzt E.;
RT   "RSUME enhances glucocorticoid receptor SUMOylation and transcriptional
RT   activity.";
RL   Mol. Cell. Biol. 33:2116-2127(2013).
RN   [24]
RP   FUNCTION.
RX   PubMed=15220929; DOI=10.1038/nn1276;
RA   Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S.,
RA   Seckl J.R., Dymov S., Szyf M., Meaney M.J.;
RT   "Epigenetic programming by maternal behavior.";
RL   Nat. Neurosci. 7:847-854(2004).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 434-525.
RX   PubMed=1865905; DOI=10.1038/352497a0;
RA   Luisi B.F., Xu W.X., Otwinowski Z., Freedman L.P., Yamamoto K.R.,
RA   Sigler P.B.;
RT   "Crystallographic analysis of the interaction of the glucocorticoid
RT   receptor with DNA.";
RL   Nature 352:497-505(1991).
RN   [26]
RP   STRUCTURE BY NMR OF 440-510.
RX   PubMed=2115209; DOI=10.1126/science.2115209;
RA   Haerd T., Kellenbach E., Boelens R., Maler B.A., Dahlman K., Freedman L.P.,
RA   Carlstedt-Duke J., Yamamoto K.R., Gustafsson J.-A., Kaptein R.;
RT   "Solution structure of the glucocorticoid receptor DNA-binding domain.";
RL   Science 249:157-160(1990).
RN   [27]
RP   STRUCTURE BY NMR OF 440-525.
RX   PubMed=1751485; DOI=10.1021/bi00114a003;
RA   Remerowski M.L., Kellenbach E., Boelens R., van der Marel A.,
RA   van Boom J.H., Maler B.A., Yamamoto K.R., Kaptein R.;
RT   "1H NMR studies of DNA recognition by the glucocorticoid receptor: complex
RT   of the DNA binding domain with a half-site response element.";
RL   Biochemistry 30:11620-11624(1991).
RN   [28]
RP   STRUCTURE BY NMR OF 440-525.
RX   PubMed=1936288; DOI=10.1016/0014-5793(91)81322-y;
RA   Kellenbach E., Maler B.A., Yamamoto K.R., Boelens R., Kaptein R.;
RT   "Identification of the metal coordinating residues in the DNA binding
RT   domain of the glucocorticoid receptor by 113Cd-1H heteronuclear NMR
RT   spectroscopy.";
RL   FEBS Lett. 291:367-370(1991).
RN   [29]
RP   STRUCTURE BY NMR OF 439-510.
RX   PubMed=8257681; DOI=10.1021/bi00212a011;
RA   Baumann H., Paulsen K., Kovacs H., Berglund H., Wright A.P.H.,
RA   Gustafsson J.-A., Haerd T.;
RT   "Refined solution structure of the glucocorticoid receptor DNA-binding
RT   domain.";
RL   Biochemistry 32:13463-13471(1993).
RN   [30]
RP   POLYMORPHISM OF POLY-GLN REGION.
RX   PubMed=8493115; DOI=10.1093/nar/21.8.2014;
RA   Gearing K.L., Gustafsson J.-A., Okret S.;
RT   "Heterogeneity in the polyglutamine tract of the glucocorticoid receptor
RT   from different rat strains.";
RL   Nucleic Acids Res. 21:2014-2014(1993).
CC   -!- FUNCTION: Receptor for glucocorticoids (GC). Has a dual mode of action:
CC       as a transcription factor that binds to glucocorticoid response
CC       elements (GRE), both for nuclear and mitochondrial DNA, and as a
CC       modulator of other transcription factors. Affects inflammatory
CC       responses, cellular proliferation and differentiation in target
CC       tissues. Involved in chromatin remodeling (PubMed:12917342). Plays a
CC       role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs
CC       and interacting with PNRC2 in a ligand-dependent manner which recruits
CC       the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to
CC       RNA decay (By similarity). Could act as a coactivator for STAT5-
CC       dependent transcription upon growth hormone (GH) stimulation and could
CC       reveal an essential role of hepatic GR in the control of body growth
CC       (By similarity). In response to induction by transcription factor
CC       EGR1/NGFI-A in the hippocampus, may play a role in the behavioral and
CC       hypothalamic-pituitary-adrenal responses to stress in offspring
CC       (PubMed:15220929). {ECO:0000250|UniProtKB:P04150,
CC       ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:12917342}.
CC   -!- FUNCTION: [Isoform A]: Has transcriptional activation and repression
CC       activity. Mediates glucocorticoid-induced apoptosis. Promotes accurate
CC       chromosome segregation during mitosis. May act as a tumor suppressor.
CC       May play a negative role in adipogenesis through the regulation of
CC       lipolytic and antilipogenic gene expression.
CC       {ECO:0000250|UniProtKB:P04150, ECO:0000250|UniProtKB:P06537}.
CC   -!- SUBUNIT: Interacts with GRIP1 (By similarity). Heteromultimeric
CC       cytoplasmic complex with HSP90AA1, HSPA1A/HSPA1B, and FKBP5 or another
CC       immunophilin such as PPID, STIP1, or the immunophilin homolog PPP5C
CC       (PubMed:21730050). Upon ligand binding FKBP5 dissociates from the
CC       complex and FKBP4 takes its place, thereby linking the complex to
CC       dynein and mediating transport to the nucleus, where the complex
CC       dissociates (By similarity). Probably forms a complex composed of
CC       chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client
CC       protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain
CC       co-chaperones STIP1/HOP and PTGES3/p23 (By similarity). Directly
CC       interacts with UNC45A (By similarity). Binds to DNA as a homodimer, and
CC       as heterodimer with NR3C2 or the retinoid X receptor (By similarity).
CC       Binds STAT5A and STAT5B homodimers and heterodimers (By similarity).
CC       Interacts with NRIP1, POU2F1, POU2F2 and TRIM28 (PubMed:10364267,
CC       PubMed:10480874). Interacts with several coactivator complexes,
CC       including the SMARCA4 complex, CREBBP/EP300, TADA2L (Ada complex) and
CC       p160 coactivators such as NCOA2 and NCOA6 (PubMed:10866662,
CC       PubMed:9111344). Interaction with BAG1 inhibits transactivation (By
CC       similarity). Interacts with HEXIM1 and TGFB1I1 (By similarity).
CC       Interacts with NCOA1 (PubMed:12917342). Interacts with NCOA3, SMARCA4,
CC       SMARCC1, SMARCD1, and SMARCE1 (PubMed:12118039, PubMed:12917342).
CC       Interacts with CLOCK, CRY1 and CRY2 in a ligand-dependent fashion (By
CC       similarity). Interacts with CIART (By similarity). Interacts with RWDD3
CC       (PubMed:23508108). Interacts with UBE2I/UBC9 and this interaction is
CC       enhanced in the presence of RWDD3 (PubMed:23508108). Interacts with
CC       NR4A3 (via nuclear receptor DNA-binding domain), represses
CC       transcription activity of NR4A3 on the POMC promoter Nur response
CC       element (NurRE) (By similarity). Directly interacts with PNRC2 to
CC       attract and form a complex with UPF1 and DCP1A; the interaction leads
CC       to rapid mRNA degradation (By similarity). Interacts with GSK3B (By
CC       similarity). Interacts with FNIP1 and FNIP2 (By similarity). Interacts
CC       (via C-terminus) with HNRNPU (via C-terminus) (By similarity).
CC       Interacts with MCM3AP (By similarity). Interacts (via domain NR LBD)
CC       with HSP90AA1 and HSP90AB1 (By similarity). In the absence of hormonal
CC       ligand, interacts with TACC1 (By similarity). Interacts (via NR LBD
CC       domain) with ZNF764 (via KRAB domain); the interaction regulates
CC       transcription factor activity of NR3C1 by directing its actions toward
CC       certain biologic pathways (By similarity).
CC       {ECO:0000250|UniProtKB:P04150, ECO:0000250|UniProtKB:P06537,
CC       ECO:0000269|PubMed:10364267, ECO:0000269|PubMed:10480874,
CC       ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12118039,
CC       ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:21730050,
CC       ECO:0000269|PubMed:23508108, ECO:0000269|PubMed:9111344}.
CC   -!- INTERACTION:
CC       P06536; Q62667: Mvp; NbExp=2; IntAct=EBI-1187143, EBI-918333;
CC       P06536; Q63604: Ntrk2; NbExp=2; IntAct=EBI-1187143, EBI-7287667;
CC       P06536; Q15788: NCOA1; Xeno; NbExp=2; IntAct=EBI-1187143, EBI-455189;
CC       P06536; Q9BTK6: PAGR1; Xeno; NbExp=2; IntAct=EBI-1187143, EBI-2372223;
CC       P06536; P51532: SMARCA4; Xeno; NbExp=3; IntAct=EBI-1187143, EBI-302489;
CC       P06536; Q96GM5: SMARCD1; Xeno; NbExp=2; IntAct=EBI-1187143, EBI-358489;
CC   -!- SUBCELLULAR LOCATION: [Isoform A]: Cytoplasm
CC       {ECO:0000250|UniProtKB:P04150}. Nucleus {ECO:0000250|UniProtKB:P04150}.
CC       Mitochondrion {ECO:0000269|PubMed:21730050}. Cytoplasm, cytoskeleton,
CC       spindle {ECO:0000250|UniProtKB:P04150}. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome
CC       {ECO:0000250|UniProtKB:P04150}. Note=After ligand activation,
CC       translocates from the cytoplasm to the nucleus (By similarity). In the
CC       presence of NR1D1 shows a time-dependent subcellular localization,
CC       localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By
CC       similarity). Lacks this diurnal pattern of localization in the absence
CC       of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20
CC       (By similarity). {ECO:0000250|UniProtKB:P04150,
CC       ECO:0000250|UniProtKB:P06537}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=A;
CC         IsoId=P06536-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=P06536-2; Sequence=VSP_018969;
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a
CC       DNA-binding domain and a C-terminal ligand-binding domain. The ligand-
CC       binding domain is required for correct chromosome segregation during
CC       mitosis although ligand binding is not required.
CC       {ECO:0000250|UniProtKB:P04150}.
CC   -!- PTM: Acetylation by CLOCK reduces its binding to glucocorticoid
CC       response elements and its transcriptional activity. {ECO:0000250}.
CC   -!- PTM: Increased proteasome-mediated degradation in response to
CC       glucocorticoids. {ECO:0000250|UniProtKB:P04150}.
CC   -!- PTM: Phosphorylated in the absence of hormone; becomes
CC       hyperphosphorylated in the presence of glucocorticoids. The Ser-224,
CC       Ser-246 and Ser-424-phosphorylated forms are mainly cytoplasmic, and
CC       the Ser-232-phosphorylated form is nuclear. Phosphorylation at Ser-232
CC       increases transcriptional activity. Phosphorylation at Ser-224, Ser-246
CC       and Ser-424 decreases signaling capacity. Phosphorylation at Ser-424
CC       may protect from glucocorticoid-induced apoptosis. Phosphorylation at
CC       Ser-224 and Ser-232 is not required in regulation of chromosome
CC       segregation. May be dephosphorylated by PPP5C, attenuates NR3C1 action.
CC       {ECO:0000250|UniProtKB:P04150, ECO:0000250|UniProtKB:P06537}.
CC   -!- PTM: Sumoylation at Lys-297 and Lys-313 negatively regulates its
CC       transcriptional activity. Sumoylation at Lys-721 positively regulates
CC       its transcriptional activity in the presence of RWDD3. Sumoylation at
CC       Lys-297 and Lys-313 is dispensable whereas sumoylation at Lys-721 is
CC       critical for the stimulatory effect of RWDD3 on its transcriptional
CC       activity. Heat shock increases sumoylation in a RWDD3-dependent manner.
CC       {ECO:0000269|PubMed:23508108}.
CC   -!- PTM: Ubiquitinated by UBR5, leading to its degradation: UBR5
CC       specifically recognizes and binds ligand-bound NR3C1 when it is not
CC       associated with coactivators (NCOAs) (By similarity). In presence of
CC       NCOAs, the UBR5-degron is not accessible, preventing its ubiquitination
CC       and degradation (By similarity). {ECO:0000250|UniProtKB:P06537}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M14053; AAA41203.1; -; mRNA.
DR   EMBL; Y12264; CAA72938.1; -; mRNA.
DR   EMBL; AY066016; AAL66772.2; -; mRNA.
DR   EMBL; AF455050; AAL78956.1; -; mRNA.
DR   EMBL; Y00489; CAA68545.1; -; mRNA.
DR   EMBL; X69666; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X69667; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X69668; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X69669; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X69670; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A24194; QRRTG.
DR   RefSeq; NP_036708.2; NM_012576.2.
DR   PDB; 1GDC; NMR; -; A=439-510.
DR   PDB; 1GLU; X-ray; 2.90 A; A/B=440-514.
DR   PDB; 1LAT; X-ray; 1.90 A; A/B=440-515.
DR   PDB; 1R4O; X-ray; 2.50 A; A/B=440-525.
DR   PDB; 1R4R; X-ray; 3.00 A; A/B=440-525.
DR   PDB; 1RGD; NMR; -; A=440-510.
DR   PDB; 2GDA; NMR; -; A=439-510.
DR   PDB; 3FYL; X-ray; 1.63 A; A/B=440-525.
DR   PDB; 3G6P; X-ray; 1.99 A; A/B=440-525.
DR   PDB; 3G6Q; X-ray; 2.26 A; A/B=440-525.
DR   PDB; 3G6R; X-ray; 2.30 A; A/B=440-525.
DR   PDB; 3G6T; X-ray; 1.90 A; A/B=440-525.
DR   PDB; 3G6U; X-ray; 1.90 A; A/B=440-525.
DR   PDB; 3G8U; X-ray; 1.90 A; A/B=440-525.
DR   PDB; 3G8X; X-ray; 2.05 A; A/B=440-525.
DR   PDB; 3G97; X-ray; 2.08 A; A/B=440-525.
DR   PDB; 3G99; X-ray; 1.81 A; A/B=440-525.
DR   PDB; 3G9I; X-ray; 1.85 A; A/B=440-525.
DR   PDB; 3G9J; X-ray; 2.32 A; A/B=440-525.
DR   PDB; 3G9M; X-ray; 1.61 A; A/B=440-525.
DR   PDB; 3G9O; X-ray; 1.65 A; A/B=440-525.
DR   PDB; 3G9P; X-ray; 1.65 A; A/B=440-525.
DR   PDBsum; 1GDC; -.
DR   PDBsum; 1GLU; -.
DR   PDBsum; 1LAT; -.
DR   PDBsum; 1R4O; -.
DR   PDBsum; 1R4R; -.
DR   PDBsum; 1RGD; -.
DR   PDBsum; 2GDA; -.
DR   PDBsum; 3FYL; -.
DR   PDBsum; 3G6P; -.
DR   PDBsum; 3G6Q; -.
DR   PDBsum; 3G6R; -.
DR   PDBsum; 3G6T; -.
DR   PDBsum; 3G6U; -.
DR   PDBsum; 3G8U; -.
DR   PDBsum; 3G8X; -.
DR   PDBsum; 3G97; -.
DR   PDBsum; 3G99; -.
DR   PDBsum; 3G9I; -.
DR   PDBsum; 3G9J; -.
DR   PDBsum; 3G9M; -.
DR   PDBsum; 3G9O; -.
DR   PDBsum; 3G9P; -.
DR   AlphaFoldDB; P06536; -.
DR   SMR; P06536; -.
DR   BioGRID; 246578; 15.
DR   CORUM; P06536; -.
DR   DIP; DIP-38940N; -.
DR   ELM; P06536; -.
DR   IntAct; P06536; 34.
DR   STRING; 10116.ENSRNOP00000019409; -.
DR   BindingDB; P06536; -.
DR   ChEMBL; CHEMBL3368; -.
DR   DrugCentral; P06536; -.
DR   iPTMnet; P06536; -.
DR   PhosphoSitePlus; P06536; -.
DR   PaxDb; 10116-ENSRNOP00000019409; -.
DR   PeptideAtlas; P06536; -.
DR   GeneID; 24413; -.
DR   KEGG; rno:24413; -.
DR   UCSC; RGD:2741; rat. [P06536-1]
DR   AGR; RGD:2741; -.
DR   CTD; 2908; -.
DR   RGD; 2741; Nr3c1.
DR   eggNOG; KOG3575; Eukaryota.
DR   InParanoid; P06536; -.
DR   OrthoDB; 5305911at2759; -.
DR   PhylomeDB; P06536; -.
DR   Reactome; R-RNO-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand.
DR   Reactome; R-RNO-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-RNO-4090294; SUMOylation of intracellular receptors.
DR   EvolutionaryTrace; P06536; -.
DR   PRO; PR:P06536; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0099092; C:postsynaptic density, intracellular component; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0005819; C:spindle; IEA:UniProtKB-SubCell.
DR   GO; GO:0003682; F:chromatin binding; IDA:RGD.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:RGD.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0034056; F:estrogen response element binding; IBA:GO_Central.
DR   GO; GO:0031072; F:heat shock protein binding; IDA:RGD.
DR   GO; GO:0042562; F:hormone binding; IPI:RGD.
DR   GO; GO:0030544; F:Hsp70 protein binding; IDA:RGD.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0004883; F:nuclear glucocorticoid receptor activity; ISO:RGD.
DR   GO; GO:0004879; F:nuclear receptor activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0005496; F:steroid binding; IPI:RGD.
DR   GO; GO:1990239; F:steroid hormone binding; ISS:UniProtKB.
DR   GO; GO:0017025; F:TBP-class protein binding; ISO:RGD.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:RGD.
DR   GO; GO:0008270; F:zinc ion binding; TAS:RGD.
DR   GO; GO:0030325; P:adrenal gland development; ISO:RGD.
DR   GO; GO:0008209; P:androgen metabolic process; IEP:RGD.
DR   GO; GO:0048708; P:astrocyte differentiation; ISO:RGD.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IMP:RGD.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; ISS:UniProtKB.
DR   GO; GO:0071286; P:cellular response to magnesium ion; IEP:RGD.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; ISS:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; ISO:RGD.
DR   GO; GO:0006338; P:chromatin remodeling; IMP:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEP:RGD.
DR   GO; GO:0031958; P:corticosteroid receptor signaling pathway; IDA:RGD.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0010467; P:gene expression; ISO:RGD.
DR   GO; GO:0008211; P:glucocorticoid metabolic process; ISO:RGD.
DR   GO; GO:0030324; P:lung development; IEP:RGD.
DR   GO; GO:0060603; P:mammary gland duct morphogenesis; ISO:RGD.
DR   GO; GO:0042711; P:maternal behavior; ISO:RGD.
DR   GO; GO:0014004; P:microglia differentiation; ISO:RGD.
DR   GO; GO:0061744; P:motor behavior; ISO:RGD.
DR   GO; GO:0014889; P:muscle atrophy; IEP:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0031914; P:negative regulation of synaptic plasticity; IMP:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0043116; P:negative regulation of vascular permeability; IMP:RGD.
DR   GO; GO:0150076; P:neuroinflammatory response; ISO:RGD.
DR   GO; GO:0042921; P:nuclear receptor-mediated glucocorticoid signaling pathway; ISO:RGD.
DR   GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; IBA:GO_Central.
DR   GO; GO:0061051; P:positive regulation of cell growth involved in cardiac muscle cell development; IMP:RGD.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IMP:RGD.
DR   GO; GO:2000324; P:positive regulation of glucocorticoid receptor signaling pathway; IDA:RGD.
DR   GO; GO:0014049; P:positive regulation of glutamate secretion; IMP:RGD.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:RGD.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:RGD.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IDA:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0031946; P:regulation of glucocorticoid biosynthetic process; ISO:RGD.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; ISO:RGD.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; IMP:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IDA:RGD.
DR   GO; GO:0051592; P:response to calcium ion; IEP:RGD.
DR   GO; GO:0051412; P:response to corticosterone; IDA:RGD.
DR   GO; GO:0071548; P:response to dexamethasone; IEP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0014854; P:response to inactivity; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0046689; P:response to mercury ion; IEP:RGD.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; ISO:RGD.
DR   GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IMP:UniProtKB.
DR   CDD; cd07172; NR_DBD_GR_PR; 1.
DR   CDD; cd07076; NR_LBD_GR; 1.
DR   Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1.
DR   Gene3D; 1.10.565.10; Retinoid X Receptor; 1.
DR   InterPro; IPR001409; Glcrtcd_rcpt.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR050200; Nuclear_hormone_rcpt_NR3.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR48092:SF5; GLUCOCORTICOID RECEPTOR; 1.
DR   PANTHER; PTHR48092; KNIRPS-RELATED PROTEIN-RELATED; 1.
DR   Pfam; PF02155; GCR; 2.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR00528; GLCORTICOIDR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1.
DR   SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Chromatin regulator;
KW   Cytoplasm; Cytoskeleton; DNA-binding; Isopeptide bond; Lipid-binding;
KW   Metal-binding; Methylation; Mitochondrion; Nucleus; Phosphoprotein;
KW   Receptor; Reference proteome; Steroid-binding; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..795
FT                   /note="Glucocorticoid receptor"
FT                   /id="PRO_0000019941"
FT   DOMAIN          542..776
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        440..505
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         440..460
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         476..500
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..439
FT                   /note="Modulating"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          67..103
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          151..206
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          504..795
FT                   /note="Interaction with CLOCK"
FT                   /evidence="ECO:0000250"
FT   REGION          506..541
FT                   /note="Hinge"
FT   REGION          550..715
FT                   /note="Interaction with CRY1"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        67..102
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        151..171
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        187..206
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         24
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         155
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         171
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:9603939"
FT   MOD_RES         224
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9603939,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         232
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9603939,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9603939"
FT   MOD_RES         287
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   MOD_RES         499
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   MOD_RES         511
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   MOD_RES         513
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   MOD_RES         514
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   CROSSLNK        278
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   CROSSLNK        297
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:23508108"
FT   CROSSLNK        297
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   CROSSLNK        313
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:23508108"
FT   CROSSLNK        313
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04150"
FT   CROSSLNK        438
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   CROSSLNK        721
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:23508108"
FT   VAR_SEQ         1..27
FT                   /note="Missing (in isoform B)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_018969"
FT   VARIANT         77
FT                   /note="Missing (in strain: Brown Norway/Crl)"
FT   VARIANT         78..79
FT                   /note="Missing (in strain: SHR/OlaIpcv)"
FT   VARIANT         83..96
FT                   /note="Missing (in strain: Sprague-Dawley)"
FT   VARIANT         226
FT                   /note="S -> G (in strain: SHR/OlaIpcv and Brown Norway/
FT                   Crl)"
FT                   /evidence="ECO:0000269|Ref.3, ECO:0007744|PubMed:22673903"
FT   VARIANT         260
FT                   /note="N -> D (in strain: SHR/OlaIpcv and Brown Norway/
FT                   Crl)"
FT                   /evidence="ECO:0000269|Ref.3"
FT   MUTAGEN         1
FT                   /note="M->T: Abolishes expression of A-type isoforms."
FT                   /evidence="ECO:0000269|PubMed:11435610"
FT   MUTAGEN         28
FT                   /note="M->T: Abolishes expression of B-type isoforms."
FT                   /evidence="ECO:0000269|PubMed:11435610"
FT   MUTAGEN         297
FT                   /note="K->R: Enhances transcriptional activity; when
FT                   associated with R-313."
FT                   /evidence="ECO:0000269|PubMed:23508108"
FT   MUTAGEN         313
FT                   /note="K->R: Enhances transcriptional activity; when
FT                   associated with R-297."
FT                   /evidence="ECO:0000269|PubMed:23508108"
FT   MUTAGEN         481
FT                   /note="D->R: Disrupts dimerization and decreases
FT                   transcription transactivation."
FT                   /evidence="ECO:0000269|PubMed:8618925"
FT   MUTAGEN         488
FT                   /note="R->Q: Loss of chromatin specific function and
FT                   reduces chromatin remodeling. Abolishes interaction with
FT                   SMARD1."
FT                   /evidence="ECO:0000269|PubMed:12917342"
FT   MUTAGEN         500
FT                   /note="C->Y: Abolishes interaction with POU2F2."
FT                   /evidence="ECO:0000269|PubMed:10480874"
FT   MUTAGEN         501
FT                   /note="L->P: Abrogates DNA-binding and transcription
FT                   transactivation. Abolishes interaction with POU2F1 and
FT                   POU2F2."
FT                   /evidence="ECO:0000269|PubMed:10480874,
FT                   ECO:0000269|PubMed:11278286"
FT   MUTAGEN         656
FT                   /note="C->S: Strongly increases affinity for
FT                   dexamethasone."
FT                   /evidence="ECO:0000269|PubMed:1939229"
FT   MUTAGEN         721
FT                   /note="K->R: Abolishes the stimulatory effect of RWDD3 on
FT                   its transcriptional activity. Diminishes NCOA2 coactivator
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:23508108"
FT   MUTAGEN         773
FT                   /note="E->A: Abolishes interaction with NCOA1 and reduces
FT                   transcription transactivation; when associated with S-656."
FT                   /evidence="ECO:0000269|PubMed:12118039"
FT   CONFLICT        95..96
FT                   /note="Missing (in Ref. 3; AAL78956)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        98
FT                   /note="D -> G (in Ref. 1; AAA41203)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        345
FT                   /note="S -> T (in Ref. 4; CAA68545)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="L -> P (in Ref. 2; CAA72938 and 3; AAL66772/
FT                   AAL78956)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        602
FT                   /note="L -> F (in Ref. 3; AAL66772/AAL78956)"
FT                   /evidence="ECO:0000305"
FT   TURN            441..443
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   STRAND          444..446
FT                   /evidence="ECO:0007829|PDB:3G97"
FT   STRAND          449..451
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   STRAND          454..456
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   HELIX           458..469
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   STRAND          477..480
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   HELIX           488..490
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   HELIX           493..503
FT                   /evidence="ECO:0007829|PDB:3G9M"
FT   HELIX           509..513
FT                   /evidence="ECO:0007829|PDB:3G9M"
SQ   SEQUENCE   795 AA;  87556 MW;  9C9DE0B1D6724845 CRC64;
     MDSKESLAPP GRDEVPGSLL GQGRGSVMDF YKSLRGGATV KVSASSPSVA AASQADSKQQ
     RILLDFSKGS TSNVQQRQQQ QQQQQQQQQQ QQQQQQPDLS KAVSLSMGLY MGETETKVMG
     NDLGYPQQGQ LGLSSGETDF RLLEESIANL NRSTSVPENP KSSTSATGCA TPTEKEFPKT
     HSDASSEQQN RKSQTGTNGG SVKLYPTDQS TFDLLKDLEF SAGSPSKDTN ESPWRSDLLI
     DENLLSPLAG EDDPFLLEGN TNEDCKPLIL PDTKPKIKDT GDTILSSPSS VALPQVKTEK
     DDFIELCTPG VIKQEKLGPV YCQASFSGTN IIGNKMSAIS VHGVSTSGGQ MYHYDMNTAS
     LSQQQDQKPV FNVIPPIPVG SENWNRCQGS GEDSLTSLGA LNFPGRSVFS NGYSSPGMRP
     DVSSPPSSSS AATGPPPKLC LVCSDEASGC HYGVLTCGSC KVFFKRAVEG QHNYLCAGRN
     DCIIDKIRRK NCPACRYRKC LQAGMNLEAR KTKKKIKGIQ QATAGVSQDT SENPNKTIVP
     AALPQLTPTL VSLLEVIEPE VLYAGYDSSV PDSAWRIMTT LNMLGGRQVI AAVKWAKAIL
     GLRNLHLDDQ MTLLQYSWMF LMAFALGWRS YRQSSGNLLC FAPDLIINEQ RMSLPCMYDQ
     CKHMLFVSSE LQRLQVSYEE YLCMKTLLLL SSVPKEGLKS QELFDEIRMT YIKELGKAIV
     KREGNSSQNW QRFYQLTKLL DSMHEVVENL LTYCFQTFLD KTMSIEFPEM LAEIITNQIP
     KYSNGNIKKL LFHQK
//
